cro in singapore

CRO Market in Singapore

P4E3-52

March 2011

2P4E3-52

Disclaimer

Frost & Sullivan takes no responsibility for any incorrect information supplied to us by manufacturers or users.

Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.

Frost & Sullivan Research Services are limited publications containing valuable market information provided to aselect group of customers in response to orders. Our customers acknowledge, when ordering, thatFrost & Sullivan Research Services are for customers internal use and not for general publication or disclosureto third parties.

No part of this Research Service may be given, lent, resold or disclosed to non-customers without writtenpermission.

Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by anymeans, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publisher.

For information regarding permission, write to:

Frost & Sullivan (M) Sdn. Bhd.

Suite E-08-15, Block E, Plaza Mont Kiara

2, Jalan Kiara, Mont Kiara

50480 Kuala Lumpur.

2011 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan.

3P4E3-52

Certification

We hereby certify that the views expressed in this research service accurately reflect our views based on primaryand secondary research with industry participants, industry experts, end users, regulatory organisations, financialand investment community, and other related sources.

In addition to the above, our robust in- house forecast & benchmarking models along with the Frost & SullivanDecision Support Databases have been instrumental in the completion and publishing of this research service.

We also certify that no part of our analyst compensation was, is or will be, directly or indirectly, related to thespecific recommendations or views expressed in this service.

4P4E3-52

Table of Contents

Executive Summary 7Market Overview 10

Regulatory Environment 11Clinical Trials in Singapore 12Clinical Trial Types 13Clinical Trials by Therapeutic Areas 14

Market Engineering Measurements 15Market Engineering Measurements 16

Market Analysis 17Market Drivers 18Market Restraints 21Revenue Forecasts 23 Clinical Trial Revenue Contribution by Phase 25Private Sector Sponsors of Clinical Trials 26Research and Development Trends in Singapore 27

Competitive Analysis 28Competitive Structure 29

Decision Support Databases 30About Frost and Sullivan 37

5P4E3-52

List of Figures

CRO Market: Number of Clinical Trial Certificates Issued by the HSA (Singapore), 2000-2009 12

CRO Market: Market Drivers Ranked in Order of Impact (Singapore), 2010-2015 18

CRO Market: Market Restraints Ranked in Order of Impact (Singapore), 2010-2015 21

CRO Market: Revenue Forecasts (Singapore), 2009-2015 23

CRO Market: Competitive Structure (Singapore), 2009 29

Decision Support Database: Government Healthcare Expenditure (World), 2002-2012 31

Decision Support Database: Population Aged 65 and Above (World), 2002-2012 34

6P4E3-52

List of Charts

CRO Market: Overview of Regulatory Agencies for Clinical Trials (Singapore), 2009 11

CRO Market: Types of Clinical Trials Conducted (Singapore), 2008 and 2009 13

CRO Market: Types of Clinical Trials Conducted by Therapeutic Areas (Singapore), 2007-2009 14

CRO Market: Market Engineering Measurements (Singapore), 2009 16

CRO Market: Revenue Forecasts (Singapore), 2009-2015 24

CRO Market: Clinical Trial Revenue Contribution by Phase (Singapore), 2009-2015 25

CRO Market: Private Sector Clinical Trial Sponsors by Type (Singapore), 2009, 2012, and 2015 26

CRO Market: Total R&D Expenditure on Biomedical and Related Sciences (Singapore), 2009-2015 27

7Executive Summary

8P4E3-52

Executive Summary

Market Trends

The number of clinical trials conducted in Singapore has increased from 157 in 2000 to 262 in 2009,registering a compound annual growth rate (CAGR) of 5.9 percent.

International trials comprise more than 80.0 percent of trials and are likely to continue to make up themajority in the future. There is a growing trend towards regional trials as Japanese regulations allowdata from other countries to be accepted for drug launches in Japan.

Currently, local trials comprise less than 10.0 percent of the total trials and offer limited growthpotential as local pharmaceutical companies face challenges in raising funds.

Oncology holds the highest interest for multinational pharmaceutical companies, with clinicalpharmacology as the next highest; ophthalmology is also of growing interest.

The size of the Singapore clinical trials market (phase I to phase IV) is estimated at US$128.4 millionin 2009 and is forecasted to reach US$ 166.5 million in 2015, growing at a CAGR of 4.4%

Currently, phases II, III, and IV contribute maximum revenues to the market, but by 2015, phases IIIand IV are expected to shrink. However, government initiatives for early phase trials are expected toincrease the revenues of phase I, along with that of phase II.

There is a fairly strong interest in biomarkers research, and Singapore will continue to see strongactivity in this area due to companies making significant investments in the same. As a result, there islikely to be an increase in the number of clinical trials that incorporate biomarkers research.

9P4E3-52

Executive Summary (Contd)

Growth Segments Singapores advanced infrastructure and investment from multinational pharmaceutical companies

have made it conducive for trials, including early stage trials.

From the regulatory perspective, there is likely to be an increased number of applications for trials thatuse flexible study designs to reduce time and costs of conducting clinical research.

Growth Opportunities

With Pfizer expanding its phase I unit in Singapore, there is an opportunity for the country to attract tosimilar studies in the country. In tandem with this, abbreviated non-clinical packages (for example,fewer animal studies and shorter duration pre-clinical studies) will become more visible.

A growing emphasis on translational research within pharmaceutical R&D will help Singapore due tothe Governments $1.10 billion investments in building the countrys translational and clinical researchcapabilities.

10

Market Overview

11P4E3-52

Regulatory Environment

Clinical trial regulation is regulated by: The Medicines Act 1975 Medicines (Clinical Trials) (Amendment) Regulations

1998. Singapore Guideline for Good Clinical Practice

(SGGCP) require to be observed.

Guidelines fall within the broad framework of the InternationalConference on Harmonization of Technical Requirements forRegistration of Pharmaceuticals for Human Use (ICH). Fortechnical guidelines not covered by the ICH, reference istaken from the Food & Drug Administration (FDA) andEuropean Agency for the Evaluation of Medicinal Products(EMEA).

Regulatory approval is issued by the Health Productsregulation Group (HPRG) and Health Sciences Authority(HSA) in the form of Clinical Trial Certificates (CTC).

Pre-clinical studies do not require to be registered with theHSA. However, they are reviewed for adherence to ICH safetyrequirements prior to approval of a clinical trial.

CRO Market: Overview of Regulatory Agencies for Clinical Trials (Singapore), 2009

Health Sciences Authority

Protects and advances national health and safety

National regulator for health products Administers clinical trials for new

drugs; issues clinical trial certificates and pre-marketing product approvals

Health Promotion Board

Main driver for national health promotion and disease prevention programs

Singapore Bioethics Advisory Committee

Addresses ethical, legal, and social issues arising from biomedical sciences research

Genetic Modification Advisory Committee

Oversees and provides advice on R&D and the use and handling of genetically modified organisms

Source: Singapore Ministry of Health

12P4E3-52

Clinical Trials in Singapore

Note: All figures are rounded; the base year is 2009. Source: www.hsa.gov.sg; Frost & Sullivan

CRO Market: Number of Clinical Trials Certificates Issued by the HSA (Singapore), 2000-2009

Phase 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 CAGR (%)

I 21 19 20 24 31 44 48 47 54 54 11.1

II 44 50 52 19 49 50 35 45 61 61 3.7

III 63 68 97 91 88 90 116 135 140 108 6.2

IV 29 28 26 26 32 17 18 26 31 39 3.4

Total Trials/Year 157 165 195 160 200 201 217 253 286 262 5.9

Private Sector 126 132 156 128 160 161 174 202 229 210 -

Public Sector 31 33 39 32 40 40 43 51 57 52 -

Clinicaltrials.gov (no. of trials

started)95 98 87 104 -

These numbers show the total number of trials started each year. About 80.0 percent of the trials are initiated by industry, while 20.0 percent are initiated by investigators this is a trend consistent over

the decade. There is a variance in the number of trials recorded in clinicaltrials.gov and HSA. The latter provides a more complete picture since

obtaining a CTC is mandatory, while listing on clinicaltrials.gov is voluntary.

13P4E3-52

Clinical Trial Types

CRO Market: Types of Clinical Trials Conducted (Singapore), 2008 and 2009

International trials are likely to remain themajority of clinical trials in Singapore during thenext 2-3 years, from 2011 to 2013.

There is a growing trend toward regional trials,and this is likely to continue in the future asJapans regulations now allow trial data fromother countries to be accepted in Japan.

There is an increasing interest in conductingtrials in the region from companies based inSouth Korea, Taiwan, and China that wouldalso increase the demand for clinical researchoutsourcing in the country.

8.0 8.08.0 10.0

84.0 82.0

0.010.020.030.040.050.060.070.080.090.0

100.0

2008 2009

Clin

ical

Tria

ls (%

)

Local Trials Regional TrialsInternational Trials

Note: All figures are rounded; the base year is 2009. Source: Frost & Sullivan

14P4E3-52

Clinical Trials by Therapeutic Areas

CRO Market: Types of Clinical Trials Conducted by Therapeutic Areas (Singapore), 2007-2009

Note: the category of Others includes respiratory, central nervous system, and nephrology. Oncology remains a therapeutic area of the highest interest for multinational pharmaceuticals investing in Singapore,

followed by clinical pharmacology. There has been growing interest in ophthalmology from 2007, with trials being conducted for conditions such as glaucoma

and myopia. Cardiology and neurology have declined in percentage, with neurology decreasing to zero trials in 2009.


15

Market Engineering Measurements

16P4E3-52

Market Engineering Measurements

CRO Market: Market Engineering Measurements (Singapore), 2009


Measurement Name Measurement Trend

Market age Low growth stage Increasing

Revenues (2009) $128.4 million Increasing

Potential Revenues (maximum future market size) $166.5 million Increasing

Base year market growth rate 4.4% Increasing

Compound annual growth rate 4.4% Increasing

Degree of competition Medium Increasing

17

Market Analysis

18P4E3-52

Market Drivers

CRO Market: Market Drivers Ranked in Order of Impact (Singapore), 2010-2015

Source: Frost & Sullivan

Rank Driver 1-2 Years 3-4 Years 5-6 Years

1Strong environment in terms of infrastructure, medical talent, regulatory approvals, and IP protection will attract increasing numbers of international trials

High High High

2 Strong government commitment and investment in the biomedical sciences sector, with a focus on clinical research, will lead to the market expansion

Medium/High High Very High

3 Singapores focus on globally relevant disease areas will increase the countrys attractiveness as a favored trials market

Medium/High High High

4 Strong interest in translational medicine will lead to an increase in the number of clinical trials that incorporate biomarker research, an area of high interests for pharmaceutical MNCs

Medium Medium Medium/High

19P4E3-52

Market Drivers (Contd)

1. Strong Environment in Terms of Infrastructure, Medical Talent, Regulatory Approvals, and IP Protection will AttractIncreasing Numbers of International Trials

The strategic focus involves developing infrastructure and capabilities for early stage clinical trials through investigationalmedicine units and phase I centers.

Medical professionals and key opinion leaders are recognized as world class, whereas patient management is of globalstandards.

Pro-business environment: It takes 3 weeks to obtain clinical trial approval.

Intellectual property and copyright laws are harmonized with standards of protection prescribed by the World TradeOrganization's Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and the Berne and ParisConventions.

2. Strong Government Commitment and Investment in the Biomedical Sciences Sector, with a Focus on ClinicalResearch, will Lead to the Market Expansion

Total R&D expenditure comprised 3.0 percent of GDP in 2010.

Biomedical Sciences Initiative was being built up as fourth pillar of economy.

2006-2010: $1.10 billion committed to translational and clinical research.

3. Singapores Focus on Globally Relevant Disease Areas will Increase the Countrys Attractiveness as a Favored TrialsMarket

Singapores research initiatives and expertise are focused in cancer, eye diseases, neuroscience, metabolic diseases, andinfectious diseases. These are in line with disease areas of global concern and major pharmaceutical companies productportfolios.

This strategic alignment will attract companies to Singapore for clinical trials.

20P4E3-52

Market Drivers (Contd)

4. Strong Interest in Translational Medicine will Lead to an Increase in the Number of Clinical Trials that IncorporateBiomarker Research, an Area of High Interests for Pharmaceutical MNCs

The inclusion of translational and clinical research in the countrys Biomedical Sciences Initiative mandate has attractedsignificant investment from the industry in the recent past; for example, multi-million dollar commitments from Roche andSchering Ploughs Translational Medical Research facilities.

These investments coupled with the governments interest will allow for an increased number of clinical trials thatincorporate biomarker research, which is an area gaining traction within pharmaceutical MNCs.

21P4E3-52

Market Restraints


CRO Market: Market Restraints Ranked in Order of Impact (Singapore), 2010-2015

Rank Restraint 1-2 Years 3-4 Years 5-6 Years

1 Limited population size will restrain the expansion of late stage trials Medium Medium Medium

2 Limited talent pool results in the need to import specialized talent Low/Medium Low Low

22P4E3-52

Market Restraints (Contd)

1. Limited Population Size will Restrain the Expansion of Late Stage Trials

The countrys limited population size is not suitable for conducting trials on rare conditions and for late phase trials thatrequire large sample size. This factor is likely to restrain the growth of the clinical trials market in Singapore

Currently, India and China are the preferred choices due to their large population size.

2. Limited Talent Pool Results in the Need to Import Specialized Talent

Sources of new highly specialized talent are limited as the current workforce, while qualified, is young and has limitedexperience in this field.

Currently, several of the countrys key scientific leaders are foreigners, while there is still a relatively small number ofmedical specialists, resulting in a need to bring in specialists from the United States and Europe for clinical trials.

23P4E3-52

Revenue Forecasts

Year Revenues ($ Million) Revenue Growth Rate (%)

2009 128.4 4.4

2010 132.6 3.3

2011 138.0 4.1

2012 143.8 4.2

2013 151.3 5.2

2014 158.6 4.8

2015 166.5 5.0

CAGR (2009-2015) 4.4

CRO Market: Revenue Forecasts (Singapore), 2009-2015


24P4E3-52

Revenue Forecasts (Contd)

CRO Market: Revenue Forecasts (Singapore), 2009-2015

The clinical trials market in Singapore (phase I through phase IV) is estimated to generate $166.5 million by 2015, driven strongly by expansion in the number of early stage trials (phases I and II).

The current interest in translational medicine will intensify and will contribute to the expansion of the market in terms of an increase of trials involving biomarker research.

CAGR (2009-2015): 4.4%


128.4 132.6138.0 143.8

151.3 158.6166.5

0.0

1.0

2.0

3.0

4.0

5.0

6.0

0.0

20.0

40.0

60.0

80.0

100.0

120.0

140.0

160.0

180.0

2009 2010 2011 2012 2013 2014 2015

Rev

enue

Gro

wth

Rat

e (%

)

Rev

enue

s ($

Mill

ion)

Year

Revenues ($ Million) Revenue Growth Rate (%)

25P4E3-52

Clinical Trial Revenue Contribution by Phase

CRO Market: Clinical Trial Revenue Contribution by Phase (Singapore), 2009-2015

Corporate and government investment in translational and clinical research, along with early phase trials, will be the key reasons for the growth of the phase I and phase II segments.

The share of contribution from later stage trials is estimated to decline as Singapores relatively small population and patientpool will restrain the growth of the phase III and phase IV segments.

20.3 22.3 24.7 27.3 30.4 33.6 3733.8 36.6 39.8

43.2 47.151.2 55.5

47.3 48.449.7 51.1

52.8 54.255.527.0 25.3

23.8 22.221.0 19.7

18.5

0.020.040.060.080.0

100.0120.0140.0160.0180.0

2009 2010 2011 2012 2013 2014 2015

Rev

enue

s ($

Mill

ion)

Year

Phase I Phase II Phase III Phase IV


26P4E3-52

Private Sector Sponsors of Clinical Trials

CRO Market: Private Sector Clinical Trial Sponsors by Type (Singapore), 2009, 2012 and 2015

Multinational pharmaceutical companies contribute to nearly 80.0 percent of clinical trial revenues.

In the next few years, there will be an increase in revenue share from specialty pharmaceutical companies as well asemerging biotech/biologics companies as pharmaceutical industrys focus on these areas increases.


77.0

60.0

47.0

8.0

12.0

14.0

2.0

7.0

12.0

12.0

12.0

12.0

1.0

9.0

15.0

0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0

2009

2012

2015

Clinical Trials (%)

MNC Pharmaceutical Specialty Pharmaceutical Emerging Pharmaceutical

Biotech Company Emerging Biotech Company

27P4E3-52

Research and Development Trends in Singapore

CRO Market: Total R&D Expenditure on Biomedical and Related Sciences (Singapore), 2009-2015

0.0200.0400.0600.0800.0

1,000.01,200.01,400.01,600.0

2009 2010 2011 2012 2013 2014 2015

R&

D E

xpen

ditu

re ($

Mill

ion)

Year

Private sector R&D expenditure on biomedical and related sciences constitutes over two-fifths of the sectors R&Dexpenditure, reaffirming Singapores attractiveness as a hub for biomedical sciences.

The government has committed $1.10 billion to drive translational and clinical research (TCR). The initiative includesincreasing the base of clinician scientists and clinical research publications. A total of $90.0 million has also beencommitted to TCR programs, which focus on key disease areas such as cancer, eye diseases, and metabolic diseases.

Recent investments in Singapore include Roches announcement in 2010 to invest $134.0 million to build a TranslationalMedical Research Hub, Eli Lilly, Merck & Co, and Pfizers 2010 announcement to combine resources to form the AsianCancer Research Group (ACRG), and Abbott Nutritions investment of $75.0 million to set up a global R&D center in2009.


28

Competitive Analysis

29P4E3-52

Competitive Structure

Number of CROs in Singapore ~15

Types of Competitors Type 1 : Full service multinational CROs headquartered outside Singapore

Type 2 : Full service CROs headquartered in Singapore with multi-Asian operations

Type 3 : Specialized services provider, e.g., preclinical only

Tiers of Competition Tier 1 : Market share more than 30.0% each

Quintiles

Tier 2 : Market share 10.0%-20.0% each

PPD, Covance, Parexel

Tier 3 : Market share up to 10.0% each

Maccine, Kendle, ICON, i3 Global, others

Key End-user Groups MNC pharmaceutical companies Specialty pharmaceutical companiesBiotechnology/biologics companies

CRO Market: Competitive Structure (Singapore), 2009


30

Decision Support Databases

31P4E3-52

Decision Support Databases

Decision Support Database: Government Healthcare Expenditure (World), 2002-2012Decision Support DatabaseTable Government healthcare expenditure (Bn USD)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 CAGR % (2005 - 2012)North AmericaCanada 50.8 61.6 70.7 81.4 89.8 95.7 101.5 107.0 112.1 116.7 120.7 5.79United States 718.0 765.7 824.2 891.3 999.5 1,077.2 1,158.4 1,243.4 1,332.9 1,426.8 1,531.8 8.04TOTAL 768.8 827.3 895.0 972.7 1,089.3 1,172.9 1,259.9 1,350.3 1,445.0 1,543.5 1,652.5 7.87

Latin AmericaArgentina 5.8 7.4 8.8 10.4 11.2 12.0 12.8 13.6 14.3 14.9 15.5 5.77Brazil 18.7 21.1 25.6 34.2 36.5 39.0 42.0 45.5 49.5 54.0 59.1 8.12Chile 1.7 2.0 2.6 3.2 3.7 4.2 4.7 5.3 5.8 6.4 6.9 11.58Mexico 26.8 25.9 27.4 31.6 34.1 36.6 39.3 42.0 44.8 47.5 50.2 6.83Peru 1.2 1.3 1.5 1.8 1.9 2.0 2.2 2.3 2.5 2.6 2.8 6.58Venezuela 2.2 2.2 2.8 3.3 3.7 4.2 4.7 5.2 5.9 6.6 7.6 12.69TOTAL 56.3 59.8 68.8 84.5 91.1 98.1 105.8 113.9 122.7 132.0 141.9 7.69

Asia - PacificAustralia 27.1 34.7 42.5 47.4 50.4 53.4 56.3 59.0 61.8 64.4 66.9 5.05China 24.2 27.7 32.3 37.7 43.0 48.4 54.0 59.9 66.3 73.2 81.3 11.62Hong Kong 5.4 5.6 5.9 6.5 7.1 7.8 8.6 9.6 10.6 11.7 12.9 10.34India 5.9 7.6 8.7 10.0 11.1 12.0 13.1 14.3 15.6 16.8 18.1 8.82Indonesia 2.3 2.9 3.2 3.5 4.0 4.6 5.2 6.0 6.9 7.9 9.1 14.83Japan 257.7 278.5 306.1 305.5 315.6 327.0 336.8 348.5 361.9 376.0 390.9 3.59Malaysia 1.9 2.2 2.5 2.8 3.2 3.7 4.2 4.8 5.4 6.0 6.7 13.13New Zealand 4.0 5.3 6.7 7.5 8.3 9.2 9.9 10.5 11.1 11.7 12.1 7.11Philippines 0.9 0.9 1.0 1.1 1.2 1.4 1.5 1.6 1.8 2.0 2.2 10.70Singapore 1.2 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 1.9 2.0 5.45South Korea 13.4 16.0 18.2 21.4 24.0 27.0 30.2 33.6 37.3 41.4 45.8 11.52Taiwan 11.0 11.5 12.4 14.1 15.2 16.1 17.2 18.7 19.9 21.1 22.1 6.61Thailand 2.6 3.0 3.4 3.8 4.3 4.8 5.4 6.0 6.9 8.1 9.3 13.80TOTAL 357.5 396.9 444.1 462.4 488.8 516.7 543.9 574.3 607.3 642.0 679.4 5.65

32P4E3-52

Decision Support Databases (Contd)

Decision Support DatabaseTable Government healthcare expenditure (Bn USD)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 CAGR % (2005 - 2012)Western EuropeAustria 10.7 13.5 15.5 16.2 16.9 17.5 18.1 18.7 19.2 19.7 20.2 3.15Belgium 16.1 20.9 24.3 25.7 26.8 28.0 29.1 30.1 31.1 32.1 33.1 3.68Denmark 1.7 2.1 2.5 2.6 2.7 2.9 3.0 3.2 3.3 3.5 3.6 4.76Finland 7.2 9.0 10.3 10.9 11.6 12.2 12.9 13.6 14.2 14.9 15.5 5.13France 105.7 134.6 156.6 166.3 174.8 182.9 191.3 199.0 206.4 213.9 221.0 4.14Germany 165.7 203.3 231.6 240.6 247.9 255.1 262.2 269.1 276.3 283.6 290.7 2.74Greece 6.9 9.1 10.4 11.9 12.8 13.7 14.5 15.4 16.3 17.2 18.2 6.32Iceland 0.7 0.9 1.1 1.4 1.5 1.7 1.8 1.9 2.1 2.2 2.3 7.95Ireland 7.3 9.6 11.6 12.2 13.4 14.5 15.5 16.6 17.7 18.8 19.9 7.29Italy 75.3 92.4 105.6 108.5 112.9 116.7 120.5 124.3 127.6 130.7 133.3 2.98Luxembourg 1.3 1.6 1.9 2.1 2.3 2.4 2.4 2.5 2.6 2.7 2.7 3.59Netherlands 25.6 31.3 35.7 36.2 39.8 40.7 41.8 42.9 44.4 45.9 47.3 3.88Norway 15.3 18.9 21.6 25.1 26.8 28.5 30.3 32.2 33.8 35.4 37.0 5.67Portugal 8.0 10.1 11.6 12.3 12.9 13.6 14.3 14.9 15.6 16.3 17.0 4.76Spain 35.4 46.4 55.0 63.2 67.6 71.8 76.1 80.5 84.5 88.6 92.3 5.57Sweden 18.9 24.2 28.6 29.1 30.4 31.7 33.5 35.5 37.6 39.9 42.6 5.60Switzerland 17.2 21.5 24.2 25.2 26.9 28.7 30.5 32.3 34.2 36.1 38.1 6.07United Kingdom 100.9 118.3 142.6 152.3 162.6 173.0 183.5 194.7 206.0 217.1 229.0 6.00TOTAL 619.8 767.6 890.9 941.8 990.3 1,035.3 1,081.3 1,127.3 1,172.8 1,218.6 1,263.7 4.29

Eastern EuropeCzech Republic 4.6 6.2 6.9 8.1 9.1 9.9 10.7 11.5 12.4 13.3 14.1 8.25Hungary 3.4 4.8 6.0 6.7 7.5 8.2 8.9 9.6 10.3 10.9 11.6 8.05Poland 9.1 9.9 11.0 13.0 14.3 15.4 16.6 18.0 19.3 20.6 21.9 7.79Russia 11.9 14.6 18.2 21.3 24.3 27.2 29.9 32.6 35.1 37.6 39.8 9.34Turkey 7.7 10.4 12.9 16.9 18.5 20.3 21.8 23.3 24.8 26.1 27.3 7.08TOTAL 36.6 45.9 54.9 66.0 73.7 80.9 88.0 95.1 102.0 108.5 114.7 8.21

33P4E3-52


Decision Support DatabaseTable Government healthcare expenditure (Bn USD)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 CAGR % (2005 - 2012)Middle East & AfricaEgypt 1.3 1.2 1.1 1.3 1.5 1.7 1.9 2.2 2.4 2.7 3.0 12.39Israel 5.7 6.2 6.3 6.4 6.7 7.1 7.4 7.9 8.5 9.1 9.7 6.06Saudi Arabia 6.1 6.8 7.4 8.0 8.7 9.1 9.6 10.0 10.5 11.0 11.4 5.15South Africa 3.0 4.7 6.8 6.5 6.8 7.2 7.6 8.0 8.3 8.7 9.2 5.14TOTAL 16.0 18.8 21.6 22.3 23.7 25.1 26.5 28.1 29.7 31.5 33.3 5.93

WORLD TOTAL 1,855.1 2,116.2 2,375.2 2,549.6 2,756.9 2,929.0 3,105.3 3,288.9 3,479.5 3,676.2 3,885.5 6.20Note: All figures are rounded; the base year is 2005. Source: Frost & Sullivan

Definition

Note1. Figures for 2005 are Frost & Sullivan estimates

The above figures indicate health care expenditure by government

34P4E3-52

Decision Support Database: Population Aged 65 and Above (World), 2002-2012Decision Support DatabaseTable Population aged 65 and above (Mn)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 CAGR % (2005 - 2012)North AmericaCanada 4.1 4.2 4.2 4.3 4.4 4.5 4.6 4.7 4.9 5.0 5.2 2.66United States 35.6 35.9 36.3 36.7 37.2 37.9 38.7 39.5 40.2 41.1 42.6 2.14TOTAL 39.7 40.1 40.5 41.0 41.6 42.4 43.3 44.2 45.1 46.1 47.7 2.19

Latin AmericaArgentina 4.0 4.0 4.1 4.2 4.2 4.3 4.4 4.5 4.6 4.6 4.7 1.88Brazil 10.0 10.3 10.7 11.1 11.5 11.9 12.3 12.7 13.2 13.7 14.3 3.67Chile 1.2 1.2 1.2 1.3 1.3 1.4 1.4 1.5 1.6 1.6 1.7 3.76Mexico 5.3 5.5 5.8 6.0 6.2 6.4 6.7 6.9 7.2 7.5 7.7 3.74Peru 1.3 1.4 1.4 1.5 1.5 1.6 1.6 1.7 1.7 1.8 1.8 3.35Venezuela 1.2 1.2 1.3 1.3 1.3 1.4 1.4 1.5 1.6 1.6 1.7 3.84TOTAL 22.9 23.7 24.5 25.3 26.1 27.0 27.9 28.8 29.8 30.8 31.9 3.40

Asia - PacificAustralia 2.5 2.5 2.6 2.6 2.7 2.7 2.8 2.8 2.9 3.0 3.1 2.59China 92.6 95.0 97.1 99.3 101.7 104.0 106.1 108.5 111.3 114.4 118.2 2.54Hong Kong 0.8 0.8 0.9 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.96India 48.7 49.9 51.1 52.5 54.0 55.6 57.4 59.2 61.2 63.3 65.5 3.29Indonesia 11.1 11.6 12.2 12.7 13.2 13.6 14.1 14.6 15.0 15.5 15.8 3.13Japan 23.1 23.7 24.2 24.8 25.5 26.3 27.0 27.7 28.1 28.3 29.1 2.18Malaysia 1.0 1.0 1.1 1.1 1.2 1.2 1.2 1.3 1.3 1.4 1.5 3.91New Zealand 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.6 2.29Philippines 3.2 3.3 3.4 3.5 3.6 3.8 3.9 4.0 4.2 4.3 4.5 3.61Singapore 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 4.07South Korea 3.7 3.9 4.1 4.3 4.5 4.7 4.9 5.0 5.2 5.3 5.6 3.56Taiwan 2.0 2.1 2.2 2.2 2.3 2.3 2.4 2.4 2.5 2.5 2.6 2.24Thailand 4.4 4.6 4.8 5.0 5.2 5.4 5.5 5.7 5.9 6.1 6.3 3.26TOTAL 193.8 199.2 204.3 209.6 215.4 221.4 227.1 233.2 239.4 246.0 254.0 2.79


35P4E3-52

Decision Support DatabaseTable Population aged 65 and above (Mn)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 CAGR % (2005 - 2012)

Western EuropeAustria 1.3 1.3 1.3 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.5 1.38Belgium 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.9 1.9 1.9 0.99Denmark 0.8 0.8 0.8 0.8 0.8 0.8 0.9 0.9 0.9 1.0 1.0 2.81Finland 0.8 0.8 0.8 0.8 0.9 0.9 0.9 0.9 0.9 0.9 1.0 2.23France 9.7 9.8 9.9 10.0 10.0 10.0 10.1 10.2 10.3 10.5 10.8 1.26Germany 14.2 14.6 15.1 15.6 16.0 16.3 16.5 16.7 16.8 16.7 16.8 0.80Greece 1.9 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.1 0.88Iceland 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.00Ireland 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.6 2.65Italy 10.7 10.9 11.1 11.3 11.5 11.6 11.7 11.7 11.8 11.9 12.1 0.95Luxembourg 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 2.25Netherlands 2.2 2.2 2.3 2.3 2.4 2.4 2.4 2.5 2.5 2.6 2.7 2.53Norway 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.8 0.8 2.09Portugal 1.7 1.8 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.9 2.0 1.24Spain 7.0 7.1 7.1 7.1 7.2 7.2 7.3 7.4 7.5 7.5 7.6 1.00Sweden 1.5 1.6 1.6 1.6 1.6 1.6 1.7 1.7 1.8 1.8 1.8 2.37Switzerland 1.1 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.3 1.3 1.3 2.03United Kingdom 9.4 9.4 9.5 9.5 9.6 9.6 9.7 9.9 10.0 10.2 10.5 1.58TOTAL 65.4 66.4 67.4 68.4 69.3 70.0 70.8 71.7 72.4 73.3 74.6 1.24

Eastern EuropeCzech Republic 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.6 1.6 1.7 1.7 2.64Hungary 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.6 0.86Poland 4.9 5.0 5.0 5.1 5.1 5.1 5.2 5.2 5.2 5.3 5.4 0.83Russia 18.8 19.3 19.8 20.3 20.6 20.8 20.4 19.8 19.2 18.8 18.9 (1.38)Turkey 4.2 4.4 4.5 4.7 4.8 4.9 5.1 5.2 5.3 5.5 5.6 2.54TOTAL 30.8 31.6 32.3 33.0 33.5 33.9 33.7 33.3 32.9 32.8 33.2 (0.14)


36P4E3-52

Decision Support DatabaseTable Population aged 65 and above (Mn)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 CAGR % (2005 - 2012)Middle East & AfricaEgypt 3.1 3.2 3.3 3.4 3.5 3.7 3.8 4.0 4.1 4.3 4.5 4.12Israel 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.7 0.7 2.04Saudi Arabia 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.7 0.7 0.7 0.8 2.91South Africa 2.1 2.2 2.2 2.3 2.3 2.4 2.4 2.5 2.5 2.6 2.6 1.77TOTAL 6.4 6.6 6.7 6.9 7.1 7.4 7.6 7.8 8.0 8.3 8.6 3.09

WORLD TOTAL 358.9 367.4 375.7 384.3 393.1 402.0 410.3 418.9 427.6 437.4 450.1 2.28Note: All figures are rounded; the base year is 2005. Source: Frost & Sullivan

Definition

The above figures represent total midyear population aged 65 years and above


37

About Frost & Sullivan

38P4E3-52

Who is Frost & Sullivan

The Growth Consulting Company

Founded in 1961, Frost & Sullivan has over 45 years of assisting clients with their decision-makingand growth issues

Over 1,700 Growth Consultants and Industry Analysts across 32 global locations

Over 10,000 clients worldwide - emerging companies, the global 1000 and the investment community

Developers of the Growth Excellence Matrix industry leading growth positioning tool for corporateexecutives

Developers of T.E.A.M. Methodology, proprietary process to ensure that clients receive a 360o

perspective of technology, markets and growth opportunities

Three core services: Growth Partnership Services, Growth Consulting and Career Best Practices

39P4E3-52

What Makes Us Unique

Exclusively Focused on Growth

Global thought leader exclusively focused onaddressing client growth strategies and plans Team actively engaged in researching anddeveloping of growth models that enable clientsto achieve aggressive growth objectives.

Industry Breadth

Cover the broad spectrum of industries andtechnologies to provide clients with the ability tolook outside the box and discover new andinnovative ideas.

Global Perspective

32 global offices ensure that clients receive aglobal coverage/perspective based on regionalexpertise.

360o Perspective

Proprietary T.E.A.M.TM Methodology integrates all6 critical research methodologies to significantlyenhance the accuracy of decision making andlower the risk of implementing growth strategies.

Growth Monitoring

Continuously monitor changing technology,markets and economics and proactively addressclients growth initiatives and position.

Trusted Partner

Working closely with client Growth Teams helping them generate new growth initiatives andleverage all of Frost & Sullivan assets toaccelerate their growth.

40P4E3-52

T.E.A.M. Methodology

Frost & Sullivans proprietary T.E.A.M. methodology, ensures that clients have complete 360 DegreePerspective from which to drive decision-making. Technical, Econometric, Application, and Marketinformation ensures that clients have a comprehensive view of industries, markets and technology.

Technical Real-time intelligence on technology, including emerging technologies, new R&Dbreakthroughs, technology forecasting, impact analysis, groundbreakingresearch, and licensing opportunities.

Econometric In-depth qualitative and quantitative research focused on timely and criticalglobal, regional, and country specific trends, including the political,demographic, and socioeconomic landscapes.

Application Insightful strategies, networking opportunities, and best practices that can beapplied for enhanced market growth; interactions between the client, peers,and Frost & Sullivan representatives that result in added value andeffectiveness.

Market Global and regional market analysis, including drivers and restraints, markettrends, regulatory changes, competitive insights, growth forecasts, industrychallenges, strategic recommendations, and end-user perspectives.

41P4E3-52

Global Perspective

1,700 staff across every major market worldwide

Over 10,000 clients worldwide from emerging to global 1000 companies

CRO Market in SingaporeDisclaimerCertificationSlide Number 4List of FiguresList of Charts Executive SummaryExecutive SummaryExecutive Summary (Contd)Market OverviewRegulatory EnvironmentClinical Trials in Singapore Clinical Trial TypesClinical Trials by Therapeutic AreasMarket Engineering MeasurementsMarket Engineering MeasurementsMarket AnalysisMarket Drivers Market Drivers (Contd)Market Drivers (Contd)Market RestraintsMarket Restraints (Contd)Revenue ForecastsRevenue Forecasts (Contd) Clinical Trial Revenue Contribution by PhasePrivate Sector Sponsors of Clinical TrialsResearch and Development Trends in SingaporeCompetitive AnalysisCompetitive StructureDecision Support DatabasesSlide Number 31Slide Number 32Slide Number 33Slide Number 34Slide Number 35Slide Number 36About Frost & SullivanWho is Frost & SullivanWhat Makes Us UniqueT.E.A.M. MethodologyGlobal Perspective

cro in singapore

Documents

market analysis

market restraints

market drivers

market overview

valuable market information

list of figurescro market

list of charts cro market

disclaimer frost sullivan